Literature DB >> 21681854

The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations.

Peter C van den Akker1, Marcel F Jonkman, Trebor Rengaw, Leena Bruckner-Tuderman, Cristina Has, Johann W Bauer, Alfred Klausegger, Giovanna Zambruno, Daniele Castiglia, Jemima E Mellerio, John A McGrath, Anthonie J van Essen, Robert M W Hofstra, Morris A Swertz.   

Abstract

Dystrophic epidermolysis bullosa (DEB) is a heritable blistering disorder that can be inherited autosomal dominantly (DDEB) or recessively (RDEB) and covers a group of several distinctive phenotypes. A large number of unique COL7A1 mutations have been shown to underlie DEB. Although general genotype-phenotype correlation rules have emerged, many exceptions to these rules exist, compromising disease diagnosing and genetic counseling. We therefore constructed the International DEB Patient Registry (http://www.deb-central.org), aimed at worldwide collection and sharing of phenotypic and genotypic information on DEB. As of May 2011, this MOLGENIS-based registry contains detailed information on 508 published and 71 unpublished patients and their 388 unique COL7A1 mutations, and includes all combinations of mutations. The current registry RDEB versus DDEB ratio of 4:1, if compared to prevalence figures, suggests underreporting of DDEB in the literature. Thirty-eight percent of mutations stored introduce a premature termination codon (PTC) and 43% an amino acid change. Submission wizards allow users to quickly and easily share novel information. This registry will be of great help in disease diagnosing and genetic counseling and will lead to novel insights, especially in the rare phenotypes of which there is often lack of understanding. Altogether, this registry will greatly benefit the DEB patients.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681854     DOI: 10.1002/humu.21551

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  29 in total

1.  High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa.

Authors:  Tobias Kühl; Markus Mezger; Ingrid Hausser; Rupert Handgretinger; Leena Bruckner-Tuderman; Alexander Nyström
Journal:  Mol Ther       Date:  2015-04-10       Impact factor: 11.454

2.  Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.

Authors:  Olivier Bornert; Tobias Kühl; Jeroen Bremer; Peter C van den Akker; Anna Mg Pasmooij; Alexander Nyström
Journal:  Mol Ther       Date:  2016-05-09       Impact factor: 11.454

3.  Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.

Authors:  David T Woodley; Jon Cogan; Yingping Hou; Chao Lyu; M Peter Marinkovich; Douglas Keene; Mei Chen
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

Review 4.  Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Velina S Atanasova; Qiujie Jiang; Marco Prisco; Christina Gruber; Josefina Piñón Hofbauer; Mei Chen; Cristina Has; Leena Bruckner-Tuderman; John A McGrath; Jouni Uitto; Andrew P South
Journal:  J Invest Dermatol       Date:  2017-05-24       Impact factor: 8.551

5.  [The many facets of inherited skin fragility].

Authors:  C Has; D Kiritsi
Journal:  Hautarzt       Date:  2014-06       Impact factor: 0.751

6.  From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB).

Authors:  Shaundra Eichstadt; Jean Y Tang; Daniel C Solis; Zurab Siprashvili; M Peter Marinkovich; Nedra Whitehead; Matthew Schu; Fang Fang; Stephen W Erickson; Mary E Ritchey; Max Colao; Kaye Spratt; Amir Shaygan; Mark J Ahn; Kavita Y Sarin
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-12-24

Review 7.  Toward Combined Cell and Gene Therapy for Genodermatoses.

Authors:  Laura De Rosa; Maria Carmela Latella; Alessia Secone Seconetti; Cecilia Cattelani; Johann W Bauer; Sergio Bondanza; Michele De Luca
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-05-01       Impact factor: 10.005

8.  Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing.

Authors:  Jose Bonafont; Angeles Mencía; Esteban Chacón-Solano; Wai Srifa; Sriram Vaidyanathan; Rosa Romano; Marta Garcia; Rosario Hervás-Salcedo; Laura Ugalde; Blanca Duarte; Matthew H Porteus; Marcela Del Rio; Fernando Larcher; Rodolfo Murillas
Journal:  Mol Ther       Date:  2021-02-18       Impact factor: 12.910

9.  Mouse models for dominant dystrophic epidermolysis bullosa carrying common human point mutations recapitulate the human disease.

Authors:  Blake R C Smith; Alexander Nyström; Cameron J Nowell; Ingrid Hausser; Christine Gretzmeier; Susan J Robertson; George A Varigos; Cristina Has; Johannes S Kern; Ken C Pang
Journal:  Dis Model Mech       Date:  2021-06-04       Impact factor: 5.758

10.  Global remodelling of cellular microenvironment due to loss of collagen VII.

Authors:  Victoria Küttner; Claudia Mack; Kristoffer T G Rigbolt; Johannes S Kern; Oliver Schilling; Hauke Busch; Leena Bruckner-Tuderman; Jörn Dengjel
Journal:  Mol Syst Biol       Date:  2013-04-16       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.